The Trump administration announced that it has reached new drug pricing agreements with nine biotech and pharmaceutical companies, and Asian pharmaceutical companies may respond in terms of stock prices. As part of the agreement, these businesses will provide discounts on outpatient medications for each state Medicaid program. States' procurement pricing will be based on the sales prices of these companies in overseas markets. Australian biopharmaceutical giant CSL said in a written statement that no significant material impact is expected in the 2027 fiscal year.

The Trump administration announced that it has reached new drug pricing agreements with nine biotech and pharmaceutical companies, and Asian pharmaceutical companies may respond in terms of stock prices. As part of the agreement, these businesses will provide discounts on outpatient medications for each state Medicaid program. States' procurement pricing will be based on the sales prices of these companies in overseas markets. Australian biopharmaceutical giant CSL said in a written statement that no significant material impact is expected in the 2027 fiscal year.